| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Equity issuance cost extinguishment | 1,078 | - | - | - |
| Other income (expense), net | 1,362 | 6,945 | -14,421 | -677 |
| Loss before provision for income tax | -10,397 | -4,439 | -26,908 | -12,371 |
| Provision for income taxes | - | 0 | - | - |
| Net loss attributable to lucid diagnostics inc | -10,397 | -4,439 | -26,908 | -12,371 |
| Less series b and series b-1 convertible preferred stock dividends earned | - | 3,449 | 9,110 | - |
| Less deemed dividend on series a and series a-1 convertible preferred stock | - | 0 | - | - |
| Net loss attributable to lucid diagnostics inc. common stockholders | -10,397 | -7,888 | -36,018 | -12,371 |
| Net loss per share attributable to lucid diagnostics inc. common stockholders - basic | -0.1 | -0.08 | -0.52 | -0.25 |
| Net loss per share attributable to lucid diagnostics inc. common stockholders - diluted | -0.1 | -0.08 | -0.52 | -0.25 |
| Weighted average common shares outstanding, basic | 108,176,088 | 98,989,161 | 68,796,392 | 50,374,146 |
| Weighted average common shares outstanding, diluted | 108,176,088 | 98,989,161 | 68,796,392 | 50,374,146 |
Lucid Diagnostics Inc. (LUCD)
Lucid Diagnostics Inc. (LUCD)